Revivegen Co., Ltd. (7578) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Revivegen Co., Ltd. TWD 7.91, price TWD 23.70, upside -66.6%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Revivegen Co., Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
52‑month range 23.70 TWD – 49.82 TWD · fair‑value band 5.54 TWD – 9.51 TWD · the 23.70 TWD price screens above the 7.91 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Revivegen Co. in your weekly email
Every Wednesday you see whether Revivegen Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Revivegen Co., Ltd. engages in the industrial waste treatment business in Taiwan. It is involved in the waste solvent physical treatment and thermal treatment activities; and provision of semiconductor cleaning agent, chip cleaning agent, paint and coating additives, and lithium battery auxiliary materials. Revivegen Co., Ltd.
Show more
Revivegen Co., Ltd. engages in the industrial waste treatment business in Taiwan. It is involved in the waste solvent physical treatment and thermal treatment activities; and provision of semiconductor cleaning agent, chip cleaning agent, paint and coating additives, and lithium battery auxiliary materials. Revivegen Co., Ltd. was founded in 2010 and is headquartered in Tainan City, Taiwan.
Stock analysis
Revivegen Co., Ltd. (7578) currently trades at 23.70 TWD, while our model-based Fair Value estimate is 7.91 TWD, implying the stock looks roughly 199.6% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 16.77 TWD per share, and 0 of the 9 models we run sit above the 23.70 TWD price.
Bear case: the Earnings-Based group reads lowest at 5.34 TWD, and 9 of the 9 models stay below the price. Evidence for this calculation is low.
Scenario range: 5.54 TWD (bear) to 9.51 TWD (bull), the price of 23.70 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Industrials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revivegen Co., Ltd. reported revenue of 469M TWD in FY2025 versus 337M TWD in FY2021, a compound +8.6%/yr. Reported net income was 20.4M TWD in FY2025, compounding −13.0%/yr from FY2021.
Key figures
Market cap 1.7B TWD (≈ $52.7M) · P/E ratio 69.7 · P/S ratio 3.03 · EPS (TTM) 0.3400 TWD · Dividend yield 1.4% · Net margin 4.3% · Return on equity 0.9% · Return on assets (EBIT) 1.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 45% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at −18% fair-value upside, at −67%, 7578 screens richer than that median.
Fair Value models
Bear 5.54 TWDFair Value 7.91 TWDBull 9.51 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.0007 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.8%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−19.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−20.6%
Dividend (yield on the price)1.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 7%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Waste Management · 168 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score25 · Bottom 25%
Fair Value upside−67% · Bottom 25%
Profitability
Return on equity (TTM)1% · Below median
Return on assets0% · Below median
Net margin (TTM)4% · Below median
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth11% · Above median
Dividend yield (TTM)1.4% · Below median
Balance sheet
Debt / equity2.10× · Highest 25%
Valuation Multiplesvs Waste Management median · lower = cheaper
P/E (TTM)69.7× · Priciest 25%
P/B1.12× · Cheaper than median
P/S (TTM)3.58× · Priciest 25%
EV/EBITDA32.6× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)57· sector 20
PAST (return on equity)3· sector 26
HEALTH (low debt)0· sector 81
DIVIDEND (yield)29· sector 44
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Revivegen Co., Ltd. (7578) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7.91 TWD versus a price of 23.70 TWD, about −67% upside (overvalued).
What is the fair value of 7578?
Our model-based fair value for Revivegen Co., Ltd. is 7.91 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 23.70 TWD.
What is the quality score of 7578?
Revivegen Co., Ltd. has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Revivegen Co., Ltd. (7578)?
Our model-based price target is the fair value of 7.91 TWD (as of Sep 24, 2026) from 9 valuation models. Cautious scenario 5.54 TWD, optimistic scenario 9.51 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Revivegen Co., Ltd. stock forecast for 2026?
Our models put fair value at 7.91 TWD, about −67% upside versus a price of 23.70 TWD (overvalued). Cautious scenario 5.54 TWD, optimistic scenario 9.51 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Revivegen Co., Ltd. (7578)?
Revivegen Co., Ltd. reported trailing-twelve-month revenue of about 469M TWD (latest available figure, as of Sep 24, 2026).
Does Revivegen Co., Ltd. pay a dividend?
Revivegen Co., Ltd. currently shows a dividend yield of about 1.43% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Revivegen Co., Ltd. (7578)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Revivegen Co., Ltd. it is 7.91 TWD per share (as of Sep 24, 2026), against a price of 23.70 TWD. It is the blended result of 9 valuation models (cash flow, earnings, asset, dividend).
Is Revivegen Co., Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 7578 trades above its calculated fair value: price 23.70 TWD, fair value 7.91 TWD, a gap of about −67% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7578?
No. The price is what the market pays today (23.70 TWD); the fair value is what the company's own numbers justify (7.91 TWD). For Revivegen Co., Ltd. the two are 15.79 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Revivegen Co., Ltd. worth?
The market values Revivegen Co., Ltd. at about 1.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 23.70 TWD; our models calculate a fair value of 7.91 TWD per share.
What do the bullish and bearish scenarios say about 7578?
Our models span a range for Revivegen Co., Ltd.: cautious scenario 5.54 TWD, base 7.91 TWD, optimistic 9.51 TWD per share (as of Sep 24, 2026, price 23.70 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 7578?
Revivegen Co., Ltd. trades at a price-to-earnings ratio of 69.7 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 7.91 TWD is built from several models across several years. Other multiples: P/B 1.1, P/S 3.6, EV/EBITDA 32.6.
How solid is the balance sheet of Revivegen Co., Ltd. (7578)?
Balance-sheet figures for Revivegen Co., Ltd. (as of Sep 24, 2026): return on equity 0.9%, debt of 2.10 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 7578 from its 52-week high?
Revivegen Co., Ltd. trades at 23.70 TWD, about 45% below its 52-week high of 43.17 TWD and at the low of 23.70 TWD (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of 7.91 TWD is for.
Which stocks are comparable to Revivegen Co., Ltd.?
From the same area (Industrials) we also value Waste Management, Inc, Republic Services, Inc, Waste Connections, Inc, Veolia Environnement SA, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Revivegen Co., Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 23.70 TWD, calculated fair value 7.91 TWD (−67%), Quality Score 25/100, from 9 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7578 calculated?
We run Revivegen Co., Ltd. through 9 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7.91 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Revivegen Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Revivegen Co., Ltd. (7578)?
The closing price on Sep 24, 2026 was 23.70 TWD. Our model-based fair value is 7.91 TWD, about −67% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Revivegen Co., Ltd. right now?
The price sits above even our optimistic bull case (9.51 TWD). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Revivegen Co., Ltd.
How large is the market capitalisation of Revivegen Co., Ltd. (7578)?
The market capitalisation of Revivegen Co., Ltd. is 1.7B TWD (≈ $52.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Revivegen Co., Ltd. (7578)?
The price-to-sales ratio of Revivegen Co., Ltd. is 3.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Revivegen Co., Ltd. (7578)?
Earnings per share at Revivegen Co., Ltd. are 0.3400 TWD (price ÷ EPS = P/E 69.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Revivegen Co., Ltd. (7578)?
The dividend yield of Revivegen Co., Ltd. is 1.4% (payout 99.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Revivegen Co., Ltd. (7578)?
The net margin of Revivegen Co., Ltd. is 4.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Revivegen Co., Ltd. (7578)?
The return on equity (ROE) of Revivegen Co., Ltd. is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Revivegen Co., Ltd. (7578)?
On an EBIT basis the return on assets of Revivegen Co., Ltd. is 1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Revivegen Co., Ltd. (7578)?
The operating margin of Revivegen Co., Ltd. is 10.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Revivegen Co., Ltd. (7578)?
Revenue at Revivegen Co., Ltd. is growing +11.3% versus a year earlier (3y avg +11.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Revivegen Co., Ltd. (7578)?
Earnings per share at Revivegen Co., Ltd. are growing +70.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Revivegen Co., Ltd. (7578) generate?
The free cash flow of Revivegen Co., Ltd. is −1.2B TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Revivegen Co., Ltd. (7578) carry?
The net debt of Revivegen Co., Ltd. is 3.2B TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Revivegen Co., Ltd. in the live analysis
One click puts Revivegen Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
